Norie Yamada, Ryuichi Sugiyama, Sayuri Nitta, Asako Murayama, Minoru Kobayashi, Chiaki Okuse, Michihiro Suzuki, Kiyomi Yasuda, Hiroshi Yotsuyanagi, Kyoji Moriya, Kazuhiko Koike, Takaji Wakita, Takanobu Kato – 9 March 2017 – The emergence of resistance mutations in the reverse transcriptase gene of hepatitis B virus (HBV) is associated with treatment failure. Entecavir (ETV) is one of the most potent anti‐HBV reagents; it has a very low resistance rate and is used as the first‐line treatment for chronic hepatitis B.

This webinar will review this latest controversy regarding the increased risk of hepatocellular carcinoma recurrence in patients receiving direct acting antiviral agents for the treatment of HCV. Recent studies have suggested that HCC recurrence is increased in HCV patients receiving direct antiviral agents.Michael D. Leise (Moderator) Dr.

Francesca Campagna, Sara Montagnese, Lorenzo Ridola, Marco Senzolo, Sami Schiff, Michele De Rui, Chiara Pasquale, Silvia Nardelli, Ilaria Pentassuglio, Carlo Merkel, Paolo Angeli, Oliviero Riggio, Piero Amodio – 8 March 2017 – Screening for hepatic encephalopathy (HE) that does not cause obvious disorientation or asterixis (minimal HE [MHE]/grade 1 HE) is important. We examined if the animal naming test (ANT1) (maximum number of animals listed in 1 minute) is useful in this context.

Lei Wang, Wen Zhang, Chang‐Hui Ge, Rong‐Hua Yin, Yang Xiao, Yi‐Qun Zhan, Miao Yu, Chang‐Yan Li, Zhi‐Qiang Ge, Xiao‐Ming Yang – 8 March 2017 – Toll‐like receptor‐5 (TLR5) signaling regulates the immune privileged status of the liver and is involved in hepatic immune disorders. However, the role of TLR5 has not yet been investigated in experimental models of concanavalin A (Con A)–mediated liver injury. Here, we show that TLR5 is highly up‐regulated in the hepatic mononuclear cells of mice during Con A–induced hepatitis.

Xiaojiaoyang Li, Runping Liu, Jing Yang, Lixin Sun, Luyong Zhang, Zhenzhou Jiang, Puneet Puri, Emily C. Gurley, Guanhua Lai, Yuping Tang, Zhiming Huang, William M. Pandak, Phillip B. Hylemon, Huiping Zhou – 8 March 2017 – The multidrug resistance 2 knockout (Mdr2–/–) mouse is a well‐established model of cholestatic cholangiopathies. Female Mdr2–/– mice develop more severe hepatobiliary damage than male Mdr2–/– mice, which is correlated with a higher proportion of taurocholate in the bile.

Francesca Campagna, Sara Montagnese, Lorenzo Ridola, Marco Senzolo, Sami Schiff, Michele De Rui, Chiara Pasquale, Silvia Nardelli, Ilaria Pentassuglio, Carlo Merkel, Paolo Angeli, Oliviero Riggio, Piero Amodio – 8 March 2017 – Screening for hepatic encephalopathy (HE) that does not cause obvious disorientation or asterixis (minimal HE [MHE]/grade 1 HE) is important. We examined if the animal naming test (ANT1) (maximum number of animals listed in 1 minute) is useful in this context.

Brian E. Hsu, Peter M. Siegel – 7 March 2017

Irwin M. Arias – 3 March 2017

Aijaz Ahmed, Stevan A. Gonzalez, George Cholankeril, Ryan B. Perumpail, Justin McGinnis, Sammy Saab, Rachel Beckerman, Zobair M. Younossi – 3 March 2017 – All‐oral direct acting antivirals (DAAs) have been shown to have high safety and efficacy in treating patients with hepatitis C virus (HCV) awaiting liver transplant (LT). However, there is limited empirical evidence comparing the health and economic outcomes associated with treating patients pre‐LT versus post‐LT.

Ying Wan, Fanyin Meng, Nan Wu, Tianhao Zhou, Julie Venter, Heather Francis, Lindsey Kennedy, Trenton Glaser, Francesca Bernuzzi, Pietro Invernizzi, Shannon Glaser, Qiaobing Huang, Gianfranco Alpini – 3 March 2017 – Substance P (SP) is involved in the proliferation of cholangiocytes in bile duct–ligated (BDL) mice and human cholangiocarcinoma growth by interacting with the neurokinin‐1 receptor (NK‐1R).